Part: 12         Session: 145678910111213141516171819202122         Page 732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792 of 999

have to make interferon. But I think they aren't going to decide that until some time in the next month.

What's an inducer?

Well, it's to stimulate the body to make interferon. But if the body's interferon supplies are deficient, it may be that the inducer won't work, and so, it's -- it seems to me that perhaps it might be wiser to make the interferon.

But this is a step that's worth investigating.

Well, they're doing it. I think I probably told you that a year ago last June 15th, Mrs. Blair, my nephew, Jim Fordyce, and Dr. Jordan Gutterman went to see Dr. Burns and Dr. Peska at Hoffman La Roche.

In Stockholm?

No. That was later. I mean, the Stockholm visit was earlier. In New Jersey, and urged Dr. Burns, who is the chief of research for Hoffman La Roche in this country, to get busy and make interferon. Jordan offered to give him white cells on which to base a purification of the material, in this year. But they're still to clone and make it on a commercial scale.

They're going to have pure material which he hopes to test in the next two months. If the present material is only .1 of 1 percent pure -- and when you think that that gives a response in certain kinds of cancers and in viruses, what will it do if you have pure material?

Yes.